Highlights

  • Profit after tax of $2.12m (Dec 2015: $1.04m; up 104%);
  • Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up 83%);
  • Revenue of $17.5m (Dec 2015: $15.7m; up 11%);
  • Profit before tax of $2.12m (Dec 2015: $1.01m; up 110%);
  • EBITDA was $2.7m (Dec 2015: $1.6m; up 69%);
  • Net Debt $5.0m (Jun 2016: $5.5m; down 9%);

The significant increase in profit was driven by improvements in the BioMedical and Healthcare divisions.

ITL BioMedical won new customers, grew its product portfolio and benefited from improved market conditions.

ITL Healthcare achieved improved profitability from strategic sourcing and customer initiatives whilst costs have been carefully controlled.

ITL's investment in MyHealthTest, the direct to consumer pathology test provider for major chronic diseases, has focused on critical systems development and expanding the range of tests.

ITL intends to continue reducing identified key risks, drive product growth and enter new markets in order to keep driving business growth.The Board expects a strong result for the full financial year even allowing for some seasonality in the 2nd half year.

Bill Mobbs Executive Chairman

ITL Limited published this content on 17 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 March 2017 13:20:19 UTC.

Original documenthttps://www.itlhealthgroup.com/article/itl-profit-doubles-in-half-year-2016-17-results/

Public permalinkhttp://www.publicnow.com/view/FFC8E3374E85B303584C3DD1CECBA2BE1E0C0A5D